Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-20

FDA Approved: ELEPSIA XR 1000 MG — Original Application (TRIPOINT THERAPEUTICS, LLC)

View source ↗

Summary

The FDA approved Elepsia XR 1000 mg, an extended-release formulation of levetiracetam, under an original NDA from TriPoint Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ELEPSIA XR 1000 MG (LEVETIRACETAM)

Snippet

ORIG AP for ELEPSIA XR 1000 MG (LEVETIRACETAM)